Leerink Partners analyst Jeffrey La Rosa raised the price target on Janux Therapeutics (NASDAQ: JANX) to $91.00 (from $79.00) while ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Janux Therapeutics (JANX) PT Raised to $115 at StifelDecember 3, 2024 8:22 AM William Blair on Janux Therapeutics (JANX): 'Exceeding Investor Expectations and Raising the Bar in mCRPC'December 3, 2024 7:06 AM Janux Therapeutics (JANX) PT Raised to $70 at H.C. WainwrightDecember 3, 2024 6:44 AM Janux Therapeutics (JANX) PT Raised to $200 at Cantor Fitzgerald, 'Mic Drop - '007 HRPC Update Waaayyy Above Expectations'December 3, 2024 6:23 AM Janux Therapeutics (JANX) call put ratio 1 call to 2.8 puts into dataDecember 3, 2024 5:30 AM Stifel Reiterates Buy Rating on Janux Therapeutics (JANX)December 3, 2024 5:27 AM Janux Therapeutics (JANX) PT Raised to $100 at BTIG, 'The World Is Not Enough — 007 Strikes Again Exceeding The Street's Highest Expectations'December 3, 2024 5:26 AM Form 8-K Janux Therapeutics, Inc. For: Dec 02December 2, 2024 5:12 PM Vir Biotechnology (VIR) Trades Higher in Sympathy with Janux Therapeutics (JANX)December 2, 2024 4:41 PM Janux Therapeutics (JANX) Surges 40% After Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPCDecember 2, 2024 4:40 PM After-hours movers: Zscaler, Honeywell, Microchip Technology and moreDecember 2, 2024 4:38 PM Janux Therapeutics (JANX) Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPCDecember 2, 2024 4:34 PM Janux Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPCDecember 2, 2024 4:30 PM